Bioharvest Sciences, Inc. (TSE:BHSC) has released an update.
Bioharvest Sciences Inc. has launched a new Contract Development and Manufacturing Organization (CDMO) unit, securing contracts to develop complex molecules for a NASDAQ-listed pharmaceutical company and a leader in the nutrition industry. Leveraging its proprietary Botanical Synthesis Process, the company offers a cost-effective and swift development of non-immunogenic BIOLOGICS+, targeting unmet needs in pharmaceutical, nutraceutical, cosmeceutical, and nutrition sectors. The development process, taking 15-24 months and costing $1.5M-$2.5M, culminates in a royalty-based production arrangement upon successful scale-up.
For further insights into TSE:BHSC stock, check out TipRanks’ Stock Analysis page.
